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Abstract  
This article presents the revised consensus criteria for the diagnosis of frontotemporal 
dysfunction in amyotrophic lateral sclerosis (ALS) based on an international research workshop 
on frontotemporal dementia (FTD) and ALS held in London, Canada in June 2015.  Since the 
publication of the Strong criteria, there have been considerable advances in the understanding of 
the neuropsychological profile of patients with ALS. Not only is the breadth and depth of 
neuropsychological findings broader than previously recognized - including deficits in social 
cognition and language – but mixed deficits may also occur. Evidence now shows that the 
neuropsychological deficits in ALS are extremely heterogeneous, affecting over 50% of persons 
with ALS. When present, these deficits significantly and adversely impact patient survival. It is 
the recognition of this clinical heterogeneity in association with neuroimaging, genetic and 
neuropathological advances that has led to the current re-conceptualization that 
neuropsychological deficits in ALS fall along a spectrum.  These revised consensus criteria 
expand upon those of 2009 and embrace the concept of the frontotemporal spectrum disorder of 
ALS (ALS-FTSD).  
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Introduction 
While the core feature of amyotrophic lateral sclerosis (ALS) is a relentless loss of motor 
function leading to paralysis and ultimately death, the awareness that it can be associated with 
one or more features of frontotemporal dysfunction has gained increasing acceptance (1).  This 
in part can be traced to the development of international criteria for the diagnosis of 
frontotemporal dysfunction in ALS in 2009 (Strong criteria) (2;3).  These criteria, which 
incorporated clinical, electrophysiological, neuropsychological, genetic and neuropathological 
characteristics, recognized that ALS could exist as a pure motor syndrome but that it can co-exist 
with a frontotemporal dementia (ALS-FTD) as defined by the Neary or Hodges criteria (4;5). 
The criteria further recognized that both behavior and/or cognitive features, not sufficient to meet 
criteria for the diagnosis of dementia but sufficient to be detected and/or give rise to impairment, 
could exist (termed ALS behavioral impairment [ALSbi] and ALS cognitive impairment 
[ALSci], respectively).  The criteria also acknowledged that a small population of patients could 
develop dementia not typical of FTD (ALS-Dementia).  
Since the introduction of the Strong criteria, our understanding of the breadth and impact 
of frontotemporal dysfunction has grown considerably. With this has come the realization that 
the Strong criteria do not adequately recognize impairments in social cognition, language or 
memory, or the presence of neuropsychiatric symptoms and that these deficits are manifestations 
of the spectrum of deficits resulting from frontotemporal dysfunction.  It is for this reason that 
we believe that the term frontotemporal spectrum disorder (ALS-FTSD) is most appropriate to 
characterize the breadth and severity of frontotemporal dysfunction that can be encountered in 
association with ALS.  Moreover, the Strong criteria were not readily adapted to languages other 
than English and were insufficiently operationalized for easy use in everyday clinical practice or 
in clinical trials.  Equally important, there have been significant advances in the genetics of ALS 
which have provided novel insights into the pathobiology of ALS-FTSD.  Given this, a 
consensus conference was convened in the summer of 2015 to revisit the 2009 Strong criteria.  A 
consensus development panel approach was utilized which consisted of a group of content 
experts (manuscript authors) who identified key topic areas of relevance to developing these 
revised international guidelines.  The expert panel then identified key international content 
experts who attended and/or presented at the international consensus conference in the summer 
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of 2015 (attendees listed in the acknowledgement section).  At the end of day 3 of the consensus 
conference, a round table discussion was held in which all attendees provided input into the key 
parameters of the revised criteria.  Members of the consensus panel formulated the revised 
criteria, following which the criteria were provided to the conference attendees for commentary 
and/or revisions. 
To that end, this article presents the revised Strong criteria.  In doing so, we have 
addressed several key issues, including the recognition that any criteria must be sufficiently 
broad to suffice for research purposes whilst at the same time be nimble enough to be of utility 
clinically.  As such, beyond expanding the nature of neuropsychological and neuropsychiatric 
deficits that characterize ALS-FTSD, a key advance in this revision is the inclusion of three 
levels of complexity or depth of assessment: criteria which can be applied in everyday clinical 
use (Level I), those which can be utilized for prognostic stratification in clinical trials (Level II), 
and those which are considered as research intensive with the goal of better defining the nature 
and extent of FTSD in ALS (Level III) (Figure 1).  The criteria are intentionally hierarchical.  
Level I incorporates tools that can be easily applied at the bedside and are of low statistical 
complexity, require the least amount of effort to implement, rely upon well-validated tools that 
have already been applied in the ALS population, and while not requiring neuropsychological 
support for implementation, would benefit from neuropsychological support for interpretation.  
Level III are the most advanced criteria and contain the core elements of the Level I testing but 
are of high statistical complexity, require a maximum amount of time and effort to complete, 
include research tools not yet validated in a broader ALS population, and would be considered 
research grade.  Level II criteria are anticipated to be applicable to clinical trials where a 
moderate amount of effort could be expended. Level II criteria also would consist of a minimum 
dataset for inclusion in case publications.  In contrast to Level I, Level II criteria require the 
engagement of either neuropsychologists or speech-language pathologists to evaluate the testing 
paradigms, to oversee or manage test administration and to interpret results. 
Participants at the consensus conference also agreed that the core features of the 
diagnostic algorithm, and most specifically the use of the diagnostic axis model, should remain 
whilst recognizing that specific components would need either modification or expansion.  Given 
this, the revised criteria continue to use the three primary ‘diagnostic axes’, including: Axis I – 
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defining the motor neuron disease variant; Axis II – defining the cognitive and behavioural 
dysfunction; and, Axis III – additional non-motor disease manifestations.  It was felt that the use 
of Axis IV which previously was included in order to define the presence of disease modifiers, 
did not contribute to the characterization of the FTSD of ALS and thus it has been omitted in the 
revised criteria presented herein. 
 
Axis I.  Defining the motor neuron disease variant 
The phenotypic variability within ALS is significant and includes variability in age of onset, site 
of onset, the degree of upper verses lower motor involvement, the rate of disease progression and 
survival.  Until such time as the basis for this heterogeneity is elucidated, it is helpful to 
recognize distinct clinical syndromes which may be characterized by the predominance of upper 
motor neuron degeneration (e.g. primary lateral sclerosis [PLS]), lower motor neuron 
neurodegeneration (e.g. progressive muscular atrophy [PMA]), or a combination of both UMN 
and LMN degeneration which typifies the most frequent phenotype, namely ALS; by the 
neuroanatomical region primarily affected (e.g. progressive bulbar palsy [PBP]); or by the 
absence (e.g. monomelic amyotrophy) or presence of left-right symmetry (e.g. brachial 
amyotrophic diplegia, also known as flail arm, or leg amyotrophic diplegia). 
 
Axis I diagnostic criteria.  Since the publication of the original Strong criteria, there has been 
considerable debate with respect to the minimal criteria necessary to diagnose ALS, particularly 
with respect to the presence or absence of active denervation as diagnostic of LMN dysfunction.  
In the original Strong criteria, it was recommended that the El Escorial criteria (revised) be used 
for the diagnosis of ALS (6-8).  In doing so, a multimodality approach toward identification of 
both UMN and LMN dysfunction using both clinical and electrodiagnostic studies was 
recommended, along with incorporation of genetic studies as appropriate.  Neuroimaging studies 
were felt to be contributory when structural pathology was considered a diagnostic possibility 
but were otherwise relegated to being a research tool.  The criteria further required the absence 
of any disease process that might account for the findings.  In this context, the diagnosis of ALS 
required the presence of multi-segmental LMN degeneration by either clinical or 
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electrophysiological criteria combined with evidence of UMN dysfunction, with progression.  
Progressive upper or lower motor neuron dysfunction in a single segment, even if isolated, was 
considered sufficient for the diagnosis in the presence of a mutation in a known ALS-causative 
gene. 
There has since been considerable debate about the genesis of the delay in diagnosing 
ALS and whether such delays may in fact hamper not only enrollment in therapeutic trials but 
the ability to impact on the earliest stages of the disease process.  This has led to the introduction 
of alternative diagnostic algorithms, the intent of which are to include greater numbers of 
patients in clinical studies or trials who may in fact have the potential of developing ALS whilst 
not yet fully manifesting the complete syndrome.  The Awaji criteria, which emerged from a 
consensus conference held in 2006, proposed two fundamental changes to the revised El Escorial 
(9).  The first proposed change was to use both electromyography and clinical data 
simultaneously to determine the presence of LMN dysfunction.  For example, atrophy in an ulnar 
innervated C8 muscle along with evidence of LMN pathology in the deltoid muscle, would be 
sufficient to declare the limb/region affected.  The second proposed change was to consider 
fasciculation potentials as evidence of ongoing denervation, equivalent in importance to 
fibrillation potentials.  While controversy has arisen over the notion that fasciculations represent 
ongoing denervation, there is greater agreement that unstable and complex fasciculations should 
be accorded greater significance.  The Awaji criteria have been shown to have a higher 
sensitivity than the El Escorial criteria (revised) while maintaining the same specificity, with the 
diagnostic benefits being most apparent in the bulbar onset and limb-onset patients (10-12).  This 
increased sensitivity, however, is gained in large part by the combination of two El Escorial 
criteria (probable and laboratory supported probable) into a single category.  The introduction of 
a “possible” diagnostic category to the Awaji criteria was of particular benefit in enhancing the 
early diagnosis of ALS and more specifically in the limb-onset subgroup (13). 
More recently, the El Escorial criteria have been revisited in an effort to accommodate a 
postulated broader ALS phenotype (14).  The revised iteration of the criteria proposed that the 
diagnosis of ALS would require, at minimum, progressive UMN and LMN deficits in at least 
one limb or region (previous possible ALS) or lower motor neuron deficits as defined by clinical 
examination (one region) and/or by EMG in two body regions (defined as bulbar, cervical, 
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thoracic, lumbosacral).  The EMG findings needed to include of neurogenic potentials and 
fibrillation potentials and/or sharp waves.  In this scheme, restricted phenotypes of ALS would 
now be considered as including progressive bulbar palsy, flail arm and flail leg syndrome, 
progressive muscular atrophy and primary lateral sclerosis.  In the context of the flail arm and 
flail leg syndromes, as well as progressive muscular atrophy, the diagnosis of ALS could be 
rendered in the absence of evidence of UMN dysfunction.  It was noted however that the 
modifications of the El Escorial criteria as proposed by Ludolph and colleagues were as yet to be 
validated in longitudinal studies, and in particular the inclusion of pure LMN syndromes, as 
being equivalent to a diagnosis of ALS.   
The role of biomarkers in the diagnosis and monitoring of progression in ALS continues 
to evolve, although to date, no markers specific to the presence of frontotemporal dysfunction 
have been validated. Thus while there is evidence to suggest that a number of biomarkers within 
either cerebrospinal fluid or blood may prove to be of value in the diagnostic work-up of ALS 
patients with or without frontotemporal dysfunction, including high molecular weight 
neurofilament, phospho-tau (including measures of total tau), TDP-43, APOE ɛ2 and beta-
amyloid are not yet ready to be included in Level I diagnostic workup (15-21).  Further, while it 
is increasingly likely that proteomic profiling of CSF will enhance the sensitivity and specificity 
of biomarker utilization in the diagnosis when used either independently or within a broader 
array of investigations including MR imaging (22;23), such testing should remain within the 
Level III workup although a restricted number (e.g., pNFH, phospho-tau, TDP-43, APOE ɛ2) 
could be considered in Level II. 
 
Axis I genetic diagnosis. Since the publication of the original consensus criteria, significant 
advances have been made in our understanding of the genetic underpinnings of ALS – there are 
now over 17 Mendelian variants known to be associated with ALS which are considered 
causative (Table 1).  In addition to these genes, an ever-expanding list of disease-associated or 
disease-modifying genes are being discovered (Supplementary Table 1).  Although these 
discoveries are helping to advance our understanding of ALS, they also add substantial 
complexity in the clinical realm.  While genetic characterization of patients with ALS and ALS-
FTSD is encouraged, it is critical to remember that the identification of a pathogenic variant in 
Deleted:  
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an ALS-causing gene does not imply the presence of disease.  Moreover, while the term 
‘familial’ remains useful in describing the presence of a family history (i.e. at least two affected 
biological relatives) and as a surrogate for the likelihood of identifying a genetic cause of 
disease, it is important to remember that all genes implicated in familial forms of ALS also have 
been found to harbor mutations in a small subset of patients with apparently sporadic ALS.  
Moreover, by virtue of factors such as recessive inheritance, compound heterozygosity, de novo 
mutations, misdiagnosis, small sibship size, reduced penetrance, lack of family information, 
including paternity, etc., a family history may frequently be lacking in genetic forms of disease.  
The term ‘familial’ therefore should not be used interchangeably with ‘genetic’(24).  Conversely, 
given a lifetime risk of ALS, which approximates 1:350 for men and 1:400 for women, 
coincidental familial clustering is a realistic consideration amongst pedigrees with only two 
affected individuals which might otherwise be considered to be clinical examples of Mendelian 
inheritance (24).   
Amongst ALS-disease causing genes, there are several that bear specific mention because 
their presence is disproportionately associated with frontotemporal dysfunction in ALS, 
sufficient to warrant genetic testing among those individuals with frontotemporal dysfunction 
regardless of the presence or absence of a family history.  The prototypic gene amongst these is 
represented by the pathological hexanucleotide repeat (GGGGCC) expansions of C9orf72 which 
is the most common genetic modification affecting fALS (60 – 70%) as well as those afflicted 
with familial FTD (approximately 18% of cases).  The presence of cognitive impairment in 
patients carrying a C9orf72 expansion is several fold greater than those without (40 – 50% vs 8 – 
9%, respectively) (25).  In rare instances in which ALS patients present with psychosis and 
marked lack of insight, there is also a higher likelihood of harbouring the pathological C9orf72 
expansion (26). 
  
Axis I recommendation.  The classification of the frontotemporal dysfunction in ALS should be 
hierarchical and begin with a description of the motor neuron disorder/syndrome. While 
consensus has not yet been achieved with respect to the use of clinical syndromic terms, we 
perceive value in the use of terms such as progressive muscular atrophy, upper motor neuron 
predominant ALS and progressive bulbar palsy, for example, and recognize that the clinical 
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syndrome may evolve over time. Such terminology is appropriately used in the clinic (Level I), 
in clinical trials (Level II) and as part of the broader research endeavor (Level III). Quite distinct 
from this syndromic nomenclature, however, is the use of diagnostic criteria such as the revised 
El Escorial and Awaji criteria for clinical trials (Level II) and research purposes (Level III).  It is 
recommended that patients diagnosed with ALS should fulfill either the El Escorial criteria 
(revised) or the Awaji criteria (revised).   
Genetic testing is recommended when a family history is present (by which we mean that 
at least one other biological relative has been diagnosed with ALS or FTD), as the El Escorial 
criteria require only progressive upper or lower motor neuron dysfunction in the presence of a 
mutation in a gene known to cause ALS. We recommend that the term ‘genetic ALS’ be used 
instead of ‘familial ALS’, especially when a genetic cause of disease is identified despite the 
absence of a family history. Appropriate genetic counseling should always be provided. For 
clinical trials (level II) and for research purposes (level III), a full genetic analysis (either a panel 
of genes established to cause ALS (Table 1), or whole exome/genome sequencing) is 
encouraged, and genetic counseling provided whenever genetic test results will be shared with 
the patient.  
 
Axis II.  Defining the neuropsychological deficits.   
The Strong criteria recognised the potential presence of FTD in ALS and for those patients not 
reaching threshold for a full FTD diagnosis, also provided a means of classifying the presence of 
cognitive or behavioural involvement: ALSci and ALSbi, respectively.  Since the publication of 
the consensus criteria in 2009, however, developments in the field have necessitated the revision 
of these definitions.  Firstly, increasing evidence has accrued as to the heterogeneity of cognitive 
impairment in ALS.  Thus while previous emphasis had been placed on executive dysfunction, 
there is now evidence that language dysfunction may be as, if not more, common and can occur 
in patients without executive dysfunction (27;28).  Deficits in social cognition also have been 
highlighted, although it is not entirely clear whether social cognition deficits are completely 
independent of executive dysfunction in ALS (29-36).  In addition, while the original ALSci and 
ALSbi classifications have been borne out by cluster analysis, it has been suggested that other 
cognitively-impaired patients cannot be classified according to the original criteria (36). There is 
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also some controversy (to be considered below) about the role of memory dysfunction in the 
classification of cognitive impairment in people with ALS.  Secondly, revised consensus criteria 
for the diagnosis of behavioural variant FTD (bvFTD) highlight the need for revising the current 
consensus criteria (37).  
Our aim, therefore, is to revise the previous classifications of cognitive and behavioural 
involvement in ALS to take into account the extended evidence base of potential deficits that 
may need to be considered in arriving at a classification of impairment and to account for the 
increased knowledge and heterogeneity of impairment profiles.  Firstly, we examine the 
developments below in specific cognitive domains that have given rise to this need for revision.  
Then we consider revisions to the classification of behavioural and neuropsychiatric symptoms 
and provide recommendations regarding testing paradigms (Supplemental Table 2). 
 
NEUROPSYCHOLOGICAL DOMAINS 
a) Executive dysfunction and Social Cognition 
Executive dysfunction is characteristic of the profile of cognitive deficits in ALS (38), a finding 
that has been confirmed through population based studies (39) and meta-analyses (40). The 
signature executive functions deficit is demonstrated through assessment of verbal fluency (41-
44).  This is a commonly used clinical instrument, involving the generation of lists of words 
beginning with a specified letter (letter fluency) or semantic category (e.g. animal fluency); the 
former being the more widely recognised marker of impairment in ALS.  Letter fluency involves 
the interaction of a number of cognitive processes, specifically executive processes of initiation, 
strategy formation, set-shifting, sustained attention and inhibition, but in addition language 
functions involved in word retrieval.  It has been shown that poor letter fluency in ALS is related 
to executive dysfunction (41).  Deficits on letter fluency tasks occur early in the course of the 
disease (45), correlate with ocular movement abnormalities (46), and are more prominent in but 
not restricted to patients with pseudobulbar palsy (42).  Based on limited published literature, 
impaired verbal fluency does not appear to be a feature of SOD1 ALS (47).   
Verbal fluency deficits in ALS also have been shown to be a marker of frontal lobe 
dysfunction, in particular the dorsolateral prefrontal cortex and inferior frontal gyrus, as 
demonstrated with functional and structural neuroimaging (48-51).  Performance in verbal 
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fluency can be affected by motor disability with difficulties in writing or in speaking which 
magnify deficits.  This has necessitated the development of the Verbal Fluency Index that 
controls for physical motor impairments by incorporating a timed condition in which the person 
either reads or copies previously generated words and from which an estimate of the average 
time taken to think of each word is calculated.  Using the Verbal Fluency Index, deficits have 
been repeatedly demonstrated which are independent of motor disability (41).   
Executive dysfunction in ALS has been revealed across a range of tests including readily 
available clinical measures and experimental procedures.  Deficits have been reliably shown on 
standard assessments measuring attention monitoring and switching, rule deduction, and 
cognitive flexibility, such as the Trail Making Test or the Wisconsin Card Sorting Test (52;53).  
A recent meta-analysis of studies using the latter revealed that patients with ALS made more 
errors (continuing to choose the previously correct rule) and took longer to learn new rules (54).  
Similar impairments have been shown on other card sorting concept formation tasks such as 
from the Delis-Kaplan Executive Function System Sorting Test (34;55).  Furthermore, deficits 
have been revealed on tests highly reliant on manipulating concepts in working memory such as 
reverse digit span or the N-Back task and most recently on tests of divided attention in which 
two tasks are undertaken concurrently, such as visual processing speed task and digit recall (51).  
Performance on standard neuropsychological tests of executive function are mostly 
mediated by functions of the dorsolateral prefrontal cortex, but studies have also revealed deficits 
using experimental measures more dependent on orbitomedial prefrontal functions.  ALS 
patients have shown abnormal risk taking on the Iowa Gambling Task (29).  Deficits have been 
shown using two more ecologically valid measures of executive functions where patients 
demonstrate difficulties in reasoning, coordinating rules and mental heuristics: the Medication 
Scheduling Task (56) and the Holiday Apartment Task (57).  
Social cognition has recently become a focus of investigation in ALS, having been a 
notable feature of the FTD profile for some time.  A recently updated meta-analysis noted the 
new addition of social cognition deficits as integral to the cognitive profile in ALS (40).  
Nevertheless there remains some debate as to the source of the deficits in social cognition with 
some studies showing an independence of executive dysfunction and others not (34;57).  Patients 
with ALS show deficits across a range of social cognitive processes including altered emotional 
processing and reduced capacity to recognize emotional (particularly negative) facial expressions 
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although this is more likely in those with ALS-FTD (29;58-60).  ALS patients also have 
difficulty on tests specific to Theory of Mind, in which the thoughts or beliefs of another are 
inferred.  One third of patients have been shown to be impaired at detecting a faux pas (57) and 
such difficulties have been related to specific problems with understanding social situations (30).  
A fundamental process in social cognition is the interpretation of the direction of eye gaze as 
assessed through the Judgement of Preference Task (29). The finding of a deficit on this task was 
extended to reveal impaired affective and to a lesser extent cognitive Theory of Mind (35).  
In patients meeting criteria for ALS-FTD, executive/social cognition deficits are a 
virtually ubiquitous feature and cover the range of difficulties described above. 
 
b) Language dysfunction 
The last two decades have seen a rising interest in defining the prevalence and the nature of the 
language impairment in ALS (27;39;61-64).  The extent to which impairments in word retrieval, 
sentence processing, spoken language, and pragmatic language are ‘pure’ language deficits 
versus downstream manifestations of other disrupted cognitive domains (e.g., executive 
function) continues to be debated.  Not all patients with ALSci present with obvious language 
impairments (65).  Moreover, language deficits in ALSci can be challenging to disentangle from 
motor speech deficits and also from ALS-FTD, which can present similarly to semantic and non-
fluent variants of primary progressive aphasia.  Notwithstanding these diagnostic challenges, an 
estimated 35-40% of individuals with ALS but no dementia may demonstrate language 
impairments (27).  These language impairments are dissociable from motor and executive 
function impairments (28;62;66-69), raising the possibility that impairments in language may 
both contribute to the profile of ALS and also occur as part of a mixed cognitive profile that 
includes executive function impairments or social cognition impairments (27;36). 
In ALS, word retrieval for nouns and object knowledge are often reported as mildly 
impaired compared with controls (28;49;62;70;71).  In contrast to nouns, verb naming and action 
verb processing deficits are a more consistent finding in ALS (27;28;62;69;71-73).  Verb deficits 
in ALS are often associated with atrophy in the dorsolateral prefrontal cortex and motor cortices 
(69;71;72).  As such, they may be an important marker of cognitive impairment in ALS.  While 
the theoretical underpinning of the object-action (i.e., noun-action verb) dissociation observed in 
ALSci remains unclear (73), these findings suggest that the assessment of word retrieval 
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impairments may benefit from including tests that measure the retrieval and comprehension of 
both nouns and action verbs. 
Sentence processing difficulties also have emerged as a prominent feature in the language 
profile of ALS (27;28;72;74;75).  Recent work suggests that syntax and sentence processing 
deficits in ALS likely exist on a spectrum with modest impairments emerging in ALS that 
progress in severity for patients with ALS-FTD (75).  While more research is needed, deficits in 
syntax processing have been dissociated from both executive function and motor speech 
impairments (28), suggesting that syntax processing impairments may contribute uniquely to the 
language profile of ALS.   
There is emerging evidence that, in addition to sentence processing deficits, individuals 
with ALS also produce sentences with a greater number of grammar and morphology errors 
compared to healthy adults (28;62;66).  Grammatical errors reported from studies of spoken 
language in ALS include incomplete utterances (28;66;68), missing determiners (66), and verb 
phrase errors (66).  Productivity deficits also characterize the spoken language of individuals 
with ALS including reduced utterance length and lower total word output, features that are likely 
related to the motor speech and respiratory challenges in ALS (28;67;68).  Beyond grammar and 
productivity impairments, other linguistic and pragmatic aspects of spoken language are affected 
in ALS including informativeness (e.g., fewer content or information words in proportion to the 
total words produced) (68;76); semantic and verbal paraphasias (28;68); poor narrative 
coherence and cohesion (66); and impaired topic management (76).  While it remains an 
evolving area of research, investigators have reported impaired pragmatic language in ALS 
including figurative and non-literal language processing, findings that are often attributed to 
frontal lobe dysfunction (76). 
Collectively, the research over the last decade underscores the importance of considering 
language impairments in the profile of ALSci.  Although analysis of spoken language tasks may 
be more challenging for typical clinical environments, due to their more labour intensive 
analyses, clinicians and researchers can glean much about the profile of language impairments in 
ALS using a number of available standardized instruments (Supplemental Table 2).   
The relationship between language impairment and ALS-FTD also is incompletely 
understood.  Progressive non-fluent aphasia (PNFA) and semantic dementia (SD) are clinical 
forms of frontotemporal lobar degeneration incorporated within previous diagnostic criteria (5).  
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Both PNFA and SD have been reported in association with ALS (77-80).  On the other hand, 
specific language problems, such as in syntactic comprehension, are reported to be common in 
patients meeting behavioural criteria for ALS-FTD (75).  Criteria for ALS-FTD need to 
recognise that language problems play a contributory role.  
 
c) Memory 
Memory deficits in ALS have been studied extensively.  However in the current 
recommendations, isolated memory impairment does not meet the criteria for a diagnosis of 
ALSci. The exclusion of memory dysfunction from the current criteria relates in part to the lack 
of consensus about the characterization of memory deficits in ALS.  Study results are wide 
ranging and have identified impairments in encoding (81-83), immediate or delayed recall 
(39;78;81;83-85), recognition (86), or the involvement of a combination of memory processes.  
Other studies suggest intact recognition memory (39;83;87).   
An updated meta-analysis in ALS showed a small effect size for delayed verbal memory 
as well as executive dysfunction, with larger effect sizes for other domains (fluency, language 
and social cognition) (40).  Although delayed verbal memory recall was associated with a greater 
effect size than visual memory (40), visual memory deficits have been detected (78).  Memory 
deficits are detected in ALS patients without dementia that correlate with grey matter 
hippocampal volumes (85) and memory scores may differ significantly from controls even in 
cognitively-normal ALS patients (78). ALS patients with baseline cognitive impairment 
demonstrate decline in verbal delayed recall when studied longitudinally (84).  
Of importance for further understanding why isolated memory involvement should not be 
used to classify ALSci, memory impairment in ALS rarely occurs in isolation (4%), which is a 
comparable rate to that seen in controls (39).  The association between executive dysfunction and 
memory impairment in ALS is asserted repeatedly (78;81-83;86;87).  Variables such as selective 
attention and mental control explain substantial variance in memory scores.  Interestingly, 
memory deficits are the least common co-morbidity in ALSci patients who present with 
executive dysfunction (39).  
With respect to the broader implications of detecting memory impairment in people with 
ALS, a population based study detected Alzheimer’s disease (AD) in 1.9% of ALS patients, 
compared to 13.8% of the sample who had FTD (39).  In a study of 279 ALS patients (78), <2% 
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met diagnostic criteria for AD, a frequency lower than the national rate of AD in 4% of the US 
population of adults below age 64 (88). In the ALS study, similarities in cognitive performance 
across cognitive diagnostic subgroups suggested different levels of severity within the same 
progressive disease subsumed by executive dysfunction.  The results did not support the presence 
of discrete subtypes (i.e. an amnestic subtype).  Qualitative differences in memory distinguish 
ALS patients from patients with AD (83) and those with the AD prodrome of mild cognitive 
impairment-amnestic type (86).   
Although isolated memory impairment does not qualify for the diagnosis of ALSci, 
memory impairment may nonetheless be problematic for patients, particularly for those in the 
older age segment of its distribution. To better understand its nature, assessment of memory in 
ALS should also analyse domains of attention, language, and executive functioning and age-
related changes in the speed of processing.  Ideally, research studies investigating memory 
should analyse multiple variables such as encoding, storage, recall, processing speed, and 
recognition rather than summarizing a single memory composite score, which may obscure the 
understanding of the specific memory deficit (86).  As with any clinical evaluation, memory 
assessment in ALS should consider alternative conditions that result in memory impairment and 
factors such as respiratory muscle weakness that may give rise to nocturnal hypoxaemia. 
Supplemental Table 2 provides a list of screening measures and comprehensive memory tests 
which can be used in the ALS population.  
 
d) Behavioural changes and neuropsychiatric symptoms 
Apathy is the most frequently identified behaviour symptom in ALS, detected in up to 70% of 
patients (89-95).  There is not a clear link to specific ALS phenotypes; apathy being pervasive, 
and severe apathy being linked to poorer prognosis in ALS (96). ALS patients may present with 
other types of behaviour change including disinhibition, loss of sympathy/egocentric behaviour, 
perseverative and stereotyped behaviour and a change in dietary habits, although not as 
commonly as apathy (91;97;98).   
When assessing behavioural change in ALS, it is important to consider potential 
confounds of respiratory insufficiency, physical disability and psychological reactions to the 
disease including mood. Reports from family members or friends are essential, especially in light 
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of the patient’s lack of insight. Baseline/premorbid psychological and behavioural status must be 
determined in order to assess whether behavioural abnormalities are 1) new, 2) associated with 
the time of onset of ALS (recognizing as stated earlier that a proportion of FTD patients will 
develop either clinical or electrophysiological features consistent with either ALS or a motor 
neuron disease), and 3) disabling or causing clear impairment.  Individuals assessing these 
patients also need to be knowledgeable about pseudobulbar affect, which may be misinterpreted 
by some as behavioural disinhibition, inappropriateness, or depression.  In turn, the distinction 
between apathy and depression is of great relevance not only for the diagnosis of ALSbi, but also 
for the clinical management of depression (when present) and provision of family support.  
It is important to acknowledge that these behavioural symptoms often co-exist with 
deficits in cognitive domains (see ALScbi; see table 3). In addition, ALSbi and ALSci can 
coexist with different levels of severity (99-101).  In some patients the combination of 
behavioural and cognitive changes are sufficient to meet criteria for ALS-FTD. 
Behavioural changes and neuropsychiatric symptoms have been merged into one 
category to align bvFTD current criteria with current research findings, as indicated in 
Supplemental Table 3. 
 
Axis II recommendations 
Since the introduction of the Strong criteria, several reliable screening and assessment tools have 
been developed with which to describe the cognitive, behavioural and language profile of an 
ALS patient. These tools have been validated and are readily applied in the clinical setting, 
allowing for brief screening or testing that can be introduced efficiently into the clinic as an 
indicator of those ALS patients who may require more intensive study (Table 3).  As such 
therefore, it is recommended that each patient receive a screening assessment as a component of 
a Level I evaluation and if impaired, that further testing is warranted.   
 
Screening and brief assessments. Screening assessments are designed firstly to identify those 
individuals who have evidence of frontotemporal dysfunction, and secondly, to provide some 
degree of differentiation as to the type of dysfunction. Where ALS screening tests are 
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administered, ALSci is identified on the basis of the published cut-off scores.  The advantage of 
using ALS screening tests such as the ECAS and ALS Cognitive Behavioral Screen (ALS-CBS) 
is that the identification of ALSci may otherwise be based on individual tests of variable levels 
of complexity, thereby contributing to the heterogeneity of identified samples. While both of 
these tools allow for the identification of ALSci, where further description of the extent of 
frontotemporal dysfunction is desirable, patients can then be assessed in greater detail using the 
tests proposed in Table 3.  To that end, it is recommended that either the ECAS or the ALS-CBS 
be administered to all patients. 
 
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS).  ECAS is a multidomain brief 
assessment developed for use within the clinic or home visits by non-neuropsychology health 
professionals (102;102).  It assesses a range of functions typically affected in ALS (ALS-
Specific: Fluency, Executive Functions, Language Functions) including newly recognised 
deficits in language and social cognition. In addition it assesses functions which are not typically 
affected in ALS but are common in disorders of older adults (ALS Non-specific: Memory, 
Visuospatial Functions).  The ECAS also includes a separate semi-structured behaviour 
interview which should be undertaken with an informant/caregiver separately from the patient 
and is based on the five key behavioural domains for diagnosing FTD (see above) using the most 
recent diagnostic criteria (37) and can therefore be used to aid in the diagnosis of behavioural 
variant FTD. 
The cognitive tests were specifically designed to allow for verbal and motor disability, 
incorporating the Verbal Fluency Index, and the whole assessment can be undertaken in either 
spoken or written format. The screen has been validated against extensive neuropsychological 
assessment and shows good sensitivity (85%) and specificity (85%) to cognitive impairment in 
ALS patients without dementia (103).  In the English versions, abnormality cut off scores were 
105/136 for ECAS-Total Score and 77/100 for ALS-Specific Score.  A five-point borderline 
range (105-110) and (77-82) produced optimal values maximizing sensitivity without a 
significant reduction of specificity and is recommended particularly for highly educated patients. 
Additionally the ECAS has been validated in German (104), Italian (105) and Chinese (106) and 
shows convergent validity with other general cognitive screening tools, including the Frontal 
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Assessment Battery and the Montreal Cognitive Assessment. The ECAS has been translated into 
a number of other languages and adapted for a North American population.  
  
ALS Cognitive Behavioral Screen (ALS-CBS).  The ALS-CBS (107) was developed as a quick, 
practical tool to aid in the identification of ALSci, ALSbi, and FTD in the clinical setting.  It 
includes a cognitive section and a caregiver questionnaire.  It has high concurrent validity with 
other ALS-specific measures (44) and has excellent accuracy (107).  High inter-rater reliability 
and ease-of-use was demonstrated in a large, multicentre study (44).  The ALS CBS has been 
translated into six languages and it has been validated in Portuguese (108) and Spanish (109).  It 
is freely available and non-copyrighted, as is ECAS.  
The ALS-CBS was developed to minimize motor or speech production involvement so 
patients can be tested during later stages of disease.  Responses can be provided verbally or in 
writing and can be generated with speech output devices or communicated with eye movements 
or mouthing. It can be administered by any clinical staff member, and requires approximately 5 
minutes to complete.  The cognitive section measures attention, concentration, working memory, 
fluency and tracking.  Only the verbal fluency item is timed.  Certain cognitive items were 
chosen based on research which identified an association between errors made on specific items 
and the severity of cognitive impairment in ALS.  Scoring combines correct responses minus 
deductions for errors, with a total possible score of 20.  Lower scores reflect greater impairment.  
Optimal cut off scores were determined in the initial validation study (107).  A cut-off of ≤10 for 
the cognitive section achieved 100% accuracy for identifying FTD in the study of ALS patients 
diagnosed with dementia based on a comprehensive neuropsychological battery.  Scores at or 
below this cut-off raise strong suspicion of FTD and should prompt further assessment to 
confirm the diagnosis.  A cut-off score of ≤16 suggests any cognitive impairment (either ALSci 
or ALS-FTD), and a score ≥17 is recommended to exclude cognitive impairment. 
The behavioural section comprises a 15-item Likert scale questionnaire completed by an 
informant and assesses change since disease onset.  Behavioural domains were selected to assess 
a variety of abnormalities known to occur in ALS and FTD, including alterations in empathy, 
personality, judgment, language, and insight. Total scores range from 0 to 45; lower scores 
indicate more pathology.  For the behavioural section, a cutoff of ≤32 achieved 86% accuracy for 
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correctly classifying ALS patients with FTD and a score of ≤36 best detects any behavioural 
impairment (ALSbi or ALS-FTD).  Scores above ≥ 37 are suggestive of normal behaviour.  
 
Domain-specific recommendations.  
ALS with cognitive impairment (ALSci).  A diagnosis of ALSci depends on evidence of either 
executive dysfunction (including social cognition) or language dysfunction or a combination of 
the two. 
Executive impairment is defined as: 
1. Impaired verbal fluency (letter).  Verbal fluency deficits must control for motor and/or 
speech impairments (41) to be valid  
OR  
2. Impairment on two other non-overlapping measures (see below) of executive functions 
(which may include social cognition). 
Language impairment is defined as: 
1.  Impairment on two non-overlapping tests (which could include pragmatic function). 
 
As the investigator or clinician elects to move to a higher level of complexity or depth of 
assessment (ie., Level II and III; see Table 3), impairment on individual measures (not screening 
tests) is defined as a score falling at or below the 5th percentile, compared to age- and education-
matched norms.  Deficits should not be better accounted for by the person’s premorbid 
intellectual level or native language, although this comparison might be best interpreted within a 
specialist clinical neuropsychological assessment.  At both Level II and III studies, carefully-
matched control groups will help inform detection of impairment.  In addition, at both Level II 
and III studies, a neuropsychologist and a speech language pathologist are considered mandatory 
to assist with the administration and interpretation of the test results.  Where individual 
assessment tools (rather than a screening or brief assessment battery) are used, the identification 
deficits on non-overlapping measures should be guided by the following considerations: 
measures of impairment should not be derived from the same test; and, tests on which 
impairment is identified should not involve a similar format (e.g. investigators would not include 
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impairment on two tests of attention-inhibition, or concept formation or two tests of naming, see 
Supplemental Table 2).  
Although the above criteria will potentially exclude people who have a selective 
breakdown on only one executive function (other than verbal fluency) or language test, we are 
concerned not to over-diagnose ALSci.  
Clinical assessments and research studies should rule out confounding factors that may or 
not may be associated with ALS.  A comprehensive assessment should rule out other cognitive 
presentations.  Assessment procedures should control for bulbar speech production impairments 
(dysarthria) and motor deficits wherever possible so that deficits are not primarily identified on 
the basis of timed tests.  Where serial measurements are available, a decline from baseline of at 
least 1.5sd on a measure might also be considered to indicate (new) impairment, although 
caution also has to be taken to evaluate the likely effect of repeated testing on performance 
where no new deficits are elicited, especially where parallel versions of tests are not available. 
For this reason, control groups are vitally important in clinical trials and longitudinal research 
studies. 
 
ALS with behavioural impairment (ALSbi).  While both the ECAS and ALS-CBS contain 
behavioural measures, the delineation of the behavioural characteristics can be further gained 
through either the Motor Neuron Disease Behaviour Scale (MiND-B) (110), the Amyotrophic 
Lateral Sclerosis-Frontotemporal Dementia-Questionnaire (ALSFTD-Q) (111) or the Frontal 
Behavioural Inventory – ALS Version (FBI-ALS) (44;112).  In each, the diagnosis of ALSbi is 
dependent on evidence from informant interviews and clinical observation of alterations in 
behaviour that cannot be accounted for by disease-related limitations, psychological reaction to 
the ALS diagnosis, a premorbid personality disorder, the presence of a comorbid psychiatric 
disorder (e.g. anxiety or depression) or pseudobulbar affect.  
 MiND-B is a brief assessment (9 items) completed by a proxy informant who knows 
well the person diagnosed by ALS. It includes three domains: disinhibition, stereotypical 
behaviour and apathy. It is derived from the Cambridge Behavioural Inventory Revised, which 
was originally developed to be sensitive for FTD. The MiND-B was validated in ALS with a 
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data driven approach. Two cut-offs to distinguish ALS from ALS plus (defined in MiND-B as 
patients with either ALSci or ALSbi) or FTD are available: 35/36: 90% sensitivity and 50% 
specificity and 33/36: 81% sensitivity and 75% specificity.  
The ALSFTD- Q is a caregiver questionnaire that was developed to measure abnormal 
behaviour change in ALS and avoid response bias due to physical disability. The 25 items were 
selected on the basis of a systematic review of the ALS literature and cover apathy, irritability, 
disinhibition, emotional lability and altered food preference. It shows good construct validity 
against other measures of behaviour change (Frontal Systems Behaviour Scale and Frontal 
Behaviour Inventory) and discriminates well ALS-FTD from ALS and controls. The cut-offs for 
this scale provide distinctions between mild behavioural symptoms (ALSbi) and more severe 
symptoms, although not for a particular behaviour.  
Loss of insight must be established by comparing patients’ and informants’ accounts of 
behavioural change and this may require clinical opinion. One means of operationalizing insight 
is to analyze standardized score discrepancies between patient self-reports and caregiver reports 
of patient behavior.  One study determined that ALS-FTD patients report significantly less 
behavioral change over time compared to their caregivers, and report fewer behavioral 
abnormalities overall (113).  The extent of patient-caregiver discrepancy was not documented in 
ALS patients without dementia. 
 
On the basis of information gained from a knowledgeable informant, a diagnosis of ALSbi is 
defined by:  
1. The identification of apathy with or without other behaviour change. 
OR  
2. The presence of two or more of the following behavioural symptoms:  a) disinhibition, b) 
loss of sympathy and empathy, c) perseverative, stereotyped or compulsive behaviour, d) 
hyperorality/dietary change, e) loss of insight (see above), f) psychotic symptoms (e.g. 
somatic delusions, hallucinations, irrational beliefs).  The behavioural features a-d, 
together with apathy, are drawn from current criteria for behavioural variant FTD (37). 
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The ECAS behaviour screen provides a checklist of symptoms from the diagnostic criteria which 
are marked as present or not. Other ALS-specific behavioural screens like the ALS-CBS and 
MiND-B provide published cut-off scores which are used to define ALSbi.    
 
ALS with combined cognitive and behavioural impairment (ALS-cbi).  This new classification 
captures patients who fulfil criteria for both ALSci and ALSbi.   
 
ALS with frontotemporal dementia (ALS-FTD).  A diagnosis of ALS-FTD is made when 
patients with ALS also show behavioural/cognitive changes in keeping with FTD.   
 
A diagnosis of ALS-FTD is defined by: 
1. Evidence of progressive deterioration of behaviour and/or cognition by observation or 
history 
AND 
2. The presence of at least 3 of the behavioural/cognitive symptoms outlined by Rascovsky 
et al  (37). 
OR 
3. The presence of at least 2 of those behavioural/cognitive symptoms, together with loss of 
insight and/or psychotic symptoms 
OR 
4. The presence of language impairment meeting criteria for semantic dementia/semantic 
variant PPA or non-fluent variant PPA, as defined by Neary et al. (5) or Gorno-Tempini 
et al,  (114). This may co-exist with behavioural/cognitive symptoms as outlined above.   
 
Neuroimaging studies in the diagnosis of a frontotemporal spectrum disorder in ALS.   
Neuroimaging continues to provide unique in vivo pathological insights into the 
expanding clinical and molecular syndrome of ALS (115).  While frontotemporal cerebral 
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atrophy may be noted during CT or MRI performed as part of the routine clinical work-up of 
ALS patients, both are insensitive and in the clinical setting a subjective assessment must take 
into account normal age-related atrophy. SPECT, long-recognised to be capable of 
demonstrating reduced frontal uptake in cases of ALS associated with dementia (116), also lacks 
essential sensitivity for ALS cases with less marked cognitive or behavioural impairment.  
Automated assessment tools for detecting more subtle grey matter volume changes on high-
resolution T1-weighted MRI (voxel-based morphometry), or frontotemporal white matter tract 
projections (diffusion tensor imaging), are not yet applicable to the individual patient. However, 
these more advanced structural MRI sequences continue to advance toward this ultimate aim 
(117), perhaps through combination with functional MRI connectivity measures (118). 
More marked patterns of basal ganglia and cerebellar structural MRI change have been 
noted in ALS patients carrying pathological hexanucleotide expansions in C9orf72 compared to 
apparently sporadic ALS cases (119;120). Furthermore, widespread structural MRI changes have 
been reported in studies involving pre-symptomatic C9orf72 mutation carriers (121;122), 
offering the potential to study the evolution of broader cerebral pathology in ALS at a much 
earlier stage. 
Positron emission tomography (PET) imaging continues to provide substantial 
knowledge regarding the anatomic and cellular topography of neuronal dysfunction in ALS, and 
increasingly, markers of non-neuronal involvement as critical mediators of the disease process.  
Advances in neuroimaging and the attendant increase in our understanding of the neural 
networks or connectome are beginning to provide greater clarity as to the nature of FTSD, and in 
particular the concept of FTSD as a disconnection syndrome with individual clinical phenotypes 
predicated on the nature of the neural network damage.  Providing crisp clinical correlates to 
such neuroimaging advances underlies a significant proportion of the impetus to revising the 
criteria. 
 
Axis III. Additional non-motor disease manifestations.  As with the 2009 Strong criteria (2), it 
is recommended that note be made of the presence or absence of non-motor manifestations, 
including extrapyramidal signs (bradykinesia, rigidity, tremor), cerebellar degeneration, 
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autonomic dysfunction, sensory impairment disproportionate to age or ocular movement 
abnormalities. 
 
Axis III recommendation. Members of the Consensus Committee made no changes to this 
recommendation.  As such, it is recommended that observations should be made of specific non-
motor manifestations that are distinct from the neuropsychiatric and neuropsychological 
manifestations of frontotemporal dysfunction. 
 
Axis IV.  Presence of disease modifiers.  In reviewing this recommendation, Members 
recognized that the majority of modifiers of the neuropsychological features of ALS would be 
captured within Axis I studies of the molecular genetics or within the specific tests of 
neuropsychology.  All studies will contain the key variables of site of disease onset, gender and 
age.  Hence, the view of the members of the consensus conference was that Axis IV was no 
longer required within the diagnostic algorithm of the frontotemporal spectrum disorders of 
ALS. 
 
Axis IV recommendation.  As noted above, members recommend that Axis IV is no longer 
required and be supplanted by information gained through the assessment of Axis I and II. 
 
Neuropathology recommendations.  The fundamental recommendations of the Strong criteria 
with respect to neuropathological diagnosis of ALS-FTSD remain unchanged.  However, in 
keeping with the consideration of levels of complexity, it is recognized that not all cases will be 
examined as extensively as was proposed, although this remains the goal.  As such, a complete 
neuropathological examination should be considered to be integral to the diagnosis, including 
examination of the brain and complete spinal cord given the high degree of regional variability 
of the disease and recent work suggesting a focal onset followed by spread (123-125).  Spinal 
cord sections should continue to include cervical, thoracic and lumbar regions.  Due to the 
pathognomonic involvement by p62 and dipeptide repeat (DPR) pathology in C9FTD/ALS, the 
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cerebellum must be included in the analysis (126;127).  In all cases, the degree of involvement of 
both the UMN and LMN should be ascertained, and for the former, when not clearly evident on 
routine haematoxylin/eosin staining, identified using immunohistochemical evidence for a 
microglial neuroinflammatory response (e.g. HLA-DR3, CD68 or Iba1) and astrogliosis (GFAP), 
and special stain (e.g. Luxol-fast blue/Nissl) for secondary myelin loss.  With the increasing 
recognition that neuronal cytoplasmic and nuclear inclusions within degenerating motor neurons 
in ALS can be composed of a broad range of cytoskeletal proteins and RNA binding proteins, 
often with multiple proteins depositing within the same degenerating motor neuron (128), there 
is now an extensive array of antibodies with which to confirm the presence of ALS.  Most 
commonly however, immunostaining with antibodies directed towards protein ubiquitination 
(ubiquitin, p62), TDP-43 and FUS and demonstrating neuronal or glial inclusions would suffice 
for the diagnosis of LMN involvement in ALS.  When full autopsy is possible, peripheral nerves 
and muscles should be part of the neuropathological work-up.  Sampling frozen tissue for future 
biochemical and genetic analysis also is recommended.   
The neuropathological correlate of FTD is frontotemporal lobar degeneration (FTLD).  
There are 3 major FTLD types depending on the hallmark pathological protein: FTLD-tau, 
FTLD-TDP and FTLD-FUS.  A small minority of FTD cases are not expressing any of these 
proteins; those reacting with markers of the ubiquitin-proteasome system (UPS) represent FTLD-
UPS whereas the rare, completely immunonegative cases fall into the group of FTLD-NOS (not 
otherwise specified).  The large majority of cases of ALS with frontotemporal dysfunction 
belong to the FTLD-TDP type and exhibit TDP-43 immunoreactive inclusions within a range of 
neocortical and subcortical structures (the remaining cases are FTLD-FUS).  They are 
predominantly in neurons in forms of neuronal cytoplasmic inclusions (NCIs), dystrophic 
neurites (DNs) and neuronal intranuclear inclusions (NIIs).  The harmonized classification 
system for FTLD-TDP recognizes four subtypes (A, B, C and D) depending on the 
morphological forms and their frequency, characteristic neuroanatomical localization and 
presence or absence of other features like hippocampal sclerosis (129).  There is good correlation 
with clinical phenotypes and genetic alterations (for example, the most frequent subtype A often 
present with bvFTD and FTD-ALS, with 50% of cases harboring GRN mutation or c9orf72 
expansion).  
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For neuropathological analysis, due to regional specificity, representative sections should 
include (among others) the anterior cingulate gyrus, precentral gyrus, superior frontal gyrus, 
superior temporal gyrus, amygdala, entorhinal cortex, hippocampus, basal ganglia and 
cerebellum.  Immunostaining should include antibodies against TDP-43, FUS, p62,  tau (e.g. 
AT8, pThr175) (130;131), -synuclein and in specific disease subtypes against neurofilament (in 
neuronal intermediate filament inclusion disease - NIFID), SOD-1, and various dipeptide repeats 
(DPRs) (in C9FTD/ALS) (132).  Assessment of the presence of amyloid beta (A) pathology 
(e.g. amyloid plaques, cerebral amyloid angiopathy) with or without Alzheimer’s disease type 
tau pathology also is mandatory.  As discussed in the original Strong criteria, neuropathological 
studies should describe, by region, the extent of neuropathological changes, including the 
presence or absence of superficial linear spongiosis, the degree of neuronal loss, the presence or 
absence of hippocampal sclerosis (including subtle focal loss of CA1 neurons), and the nature of 
inclusions present (including dystrophic neurites, neuronal cytoplasmic inclusions, and neuronal 
intranuclear inclusions).  The presence or absence of glial pathology, whether astrocytic or 
oligodendroglial, should be delineated.  A stepwise approach is recommended for 
neuropathological work-up with special stains and immunohistochemistry of the relevant brain 
and spinal cord regions (132).  A diagnostic algorithm has been proposed recently for 
neuropathological diagnosis of ALS, FTD and overlapping syndromes (132).  More details about 
the principles and practice of neuropathological analysis and key morphological features are 
described in reference textbooks (132-134). 
Since the publication of the original Strong criteria, the concept of staging of the 
frontotemporal degeneration of the neocortical and subcortical involvement in ALS has become 
increasingly of value in understanding the degree to which ALS-FTD may be a distinct entity 
from ALSci, ALS bi (and thus potentially ALScbi).  Level III studies are thus recommended to 
include a full staging analysis as delineated by Halliday and colleagues (135). 
 
Discussion. 
In contrast to the milieu in which the Strong criteria for the diagnosis of frontotemporal 
dysfunction were crafted, there is now a clearer appreciation of the significant proportion of ALS 
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patients who will have evidence of multidimensional dysfunction.  When the Strong criteria were 
applied to ALS patients prospectively, more than 50% of ALS patients were found to have some 
form of frontotemporal disruptions or dementia, including probable Alzheimer’s disease 
(39;136-139).  There is, in fact, remarkable consistency across virtually all studies.  The 
importance of recognizing these deficits lies in their impact on survival for a large proportion of 
ALS patients, an impact which is not yet integrated into the design of drug trials in ALS.  And 
yet, executive dysfunction alone is a significant predictor of reduced survival from symptom 
onset (137).  Behavioural dysfunction appears also to have an equal contribution to survival 
(p<0.001), seemingly in isolation from other variables (140).  By increasing the rigor of defining 
the deficits in ALS, this should be clarified and ultimately, become a defined variable in the 
design and analysis of clinical trials in ALS.  
Advances in our understanding of the spectrum of frontotemporal dysfunction that can 
occur in concert with the motor degeneration of ALS mandated a revision of the Strong criteria.  
Underpinning this is the realization that there exists a spectrum of deficits which have a degree 
of overlap, and hence the adoption of the term ALS frontotemporal spectrum disorders (ALS-
FTSD).  This is not meant to imply that the spectrum is a continuum, and indeed it is less clear 
that ALS-FTD is the natural endpoint of ALSci, ALSbi or ALS(cbi). 
 These revised criteria (Table 2) have addressed the issue of genetic testing more 
critically, in part driven by the explosion in knowledge of genetic mutations that are either 
causally associated with ALS, or identified as modifiers of the disease process.  The discovery 
that many of these genetic mutations can be observed in ALS patients in whom there is no 
evidence for inheritance underscores the importance of using the term ‘genetic’ rather than 
‘familial ALS’ to describe such cases.  To that extent, we have proposed that all ALS can be 
stratified into those cases for which a genetic etiology is known, versus those for which one is 
not.  Clearly, there remain cases for which the designation of familial is warranted based on a 
conventional analysis of the patient pedigree; we recommend that these cases also be subsumed 
under the terminology “genetic ALS”.  We are recommending further that all patients who are 
diagnosed as ALS-FTSD be offered the opportunity for genetic testing, and in the cases of 
research protocols, that this be mandatory.  While ideally an individual should be tested for all 
genes identified as being causally linked (Table 1), this is impractical and beyond the resources 
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of many clinics or individuals.  Genetic testing should, therefore, be modified according not only 
to the geography of origin of the patient, but to the nature of the deficit (for instance, a patient 
presenting with marked behavioural impairment, with or without psychosis, should first be tested 
for pathological hexanucleotide expansions of C9orf72). 
 Since the introduction of the Strong criteria, there also has been an increasing awareness 
that the neuropsychological deficits are pervasive across the spectrum of motor neuron diseases.  
The issue arises that even within the motor manifestations of ALS, it is increasingly recognized 
that there is considerable clinical phenotypic heterogeneity.  This observation has driven 
controversy as to the degree to which defining this heterogeneity serves any clinical purpose, as 
opposed to considering all disorders of the motor neuron to simply be, on aggregate, a single 
disorder (i.e., lumping vs. splitting).  Recent attempts at revising the diagnostic criteria for ALS 
have leaned towards the latter.  However, in developing these revised Strong criteria, it is hoped 
that a clearer and more consistent set of criteria by which to define the specific variants of 
frontotemporal dysfunction will provide a clearer understanding of distinct pathophysiology of 
frontotemporal dysfunction in ALS, and potentially, selective treatment responses.  While it 
remains unresolved whether clinically divergent presentations are due to disparate etiologies, it is 
prudent to maintain careful documentation of the clinical phenotype and encourage 
investigations that may link or associate specific presentations with unique biomarkers or 
etiologies.  The absence of maintaining awareness of such clinically divergent motor neuron 
phenotypes, given our current understanding, raises the probability of obscuring a valuable 
treatment effect or a clinical association (perhaps with FTD spectrum) that could highlight a 
critical etiology.  Hence, we have elected to maintain Axis I with a focus on defining the motor 
neuron disease succinctly. 
 Finally, as with the original Strong criteria, it is recognized that our understanding of the 
frontotemporal dysfunction which may occur in ALS will continue to evolve rapidly.  Even now, 
the place of memory and language impairments in ALS are works in progress, as is defining the 
true breadth of behavioural and neuropsychiatric dysfunction which may occur.  Moreover, 
recent investigations have begun to elucidate the influence of gender in ALS disease 
manifestation, including ALSci and ALSbi (141). At this point in time however, it is our 
intention that these revised criteria will provide a greater level of diagnostic certainty. 
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Figure legends 
Figure 1.  Schematic of levels of investigation.  The revised criteria are designed to address the need for rapid, easily applied tools 
that can be used within the clinic (Level I) through to assessment tools that are more appropriate to research studies (Level III).  
Levels II and III require formal neuropsychological and speech and language expertise to implement, reflect higher statistical 
complexity, and include tests that may require further validation in the ALS population.  Level II is an intermediary level which can 
be applied in clinical trials and would be appropriate to be included in clinical case reports as minimum datasets. 
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Supplemental Table 1.  ALS susceptibility genes and their association with ALS, FTD or ALS-FTSD (sorted by chromosome) 
Locus Gene ID/Locus 
MIM number 
Chromosome Protein; functional 
changes 
Inheritance Clinical Phenotype Reference 
     FTD ALS ALS-
FTSD 
other  
 CAMTA1 1p36.31-p36.23 Calmodulin-binding 
transcription activator 
gene 1 
sporadic n/a + n/a Cerebellar 
ataxia with 
mental 
retardation 
(1) 
 KIFAP3 1q24.2 Kinesin-associated 
protein 3; small G 
protein 
sporadic n/a + (3) n/a  (2) 
 DCTN1 2p13.1 Dynactin 1; axonal 
transport 
AD + (9) + n/a Perry 
syndrome 
(3;4) 
ALS17 CHMP2B 3p11.2 Charged multivesicular 
body protein 2B (also 
known as chromatin-
modifying protein 2B); 
Vesicle trafficking 
sporadic + + n/a  (5;6) 
 NEK1 4q33 Serine/threonine kinase 
NIMA (never in 
mitosis gene-A)-related 
kinase 
sporadic  +   (7;8) 
 ARHGEF28 5q13.2 Rho guanine nucleotide 
exchange factor 28 
AD n/a + n/a  (9-11) 
 SMN1 5q13.2 Survival of motor 
neuron 1 
AD, sporadic n/a + n/a  (12;13) 
 MATR3 5q31.2 Matrin 3; Nuclear 
matrix RNA/DNA 
binding protein  
AD + 
(10) 
+  Distal 
asymmetric 
myopathy 
(14;15) 
 SQSTM1 5q35.3 Sequestome 1; scaffold 
protein, NFkB 
AD, sporadic + + + Paget’s 
disease of 
(16;17) 
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signaling pathway bone 
 HFE 6p22.1 Hemochromatosis; iron 
absorption 
sporadic n/a + (4) n/a  (18;19) 
ALS11 FIG4 6q21 Factor-Induced gene 4 
(FIG4) homolog, SAC1 
lipid phosphatase 
domain containing 
(Saccharomyces 
cerevisiae); 
polyphosphoinositide 
phosphatase 
AD, sporadic n/a + (8) n/a PLS, CMT (20) 
 PON1 7q21.3 Paraoxonase; 
organophosphate 
hydrolysis 
sporadic n/a +  n/a  (21) 
 ELP3 8p21.1 Elongator 
acetyltransferase 
complex subunit 3; 
transcript elongation 
sporadic n/a + n/a  (22) 
ALS16 SIGMAR1 9q13.3 Sigma non-opioid 
intracellular receptor 1; 
Ion channel regulation 
AR + +   (23;24) 
 ITPR2 12p12.1-11.23 INOSITOL 1,4,5-
triphosphate receptor 
type 2 
sporadic n/a + (1) n/a  (25) 
 PRPH 12q13.12 Peripherin; 
cytoskeleton 
AD, sporadic n/a + (6) n/a  (26;27) 
 DAO 12q24.11 D-amino-acid oxidase; 
Oxidative stress 
AD  +   (28) 
ALS13 ATXN 2 12q24.12 Ataxin 2; Oxidative 
stress 
sporadic n/a + n/a SCA2 (29;30) 
ALS9 ANG 14q11.2 Angiogenin, 
ribonuclease, RNase A 
family; DNA/RNA 
AD, sporadic n/a + + (7) PD (31;32) 
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processing 
 TAF15 17q12 TAF15 RNA 
polymerase II, TATA 
box binding protein 
(TDP)-associated 
factor, 68 kDa; 
DNA/RNA processing 
AD + + (5) n/a  (33;34) 
 PGRN 17q21.31 Progranulin; cell 
growth regulator 
sporadic + + (2) n/a  (35) 
 UNC13A 19p13.12 Unc-13 homologue A 
(Caenorhabditis 
elegans); Synaptic 
neurotramsmitter 
release 
sporadic 
 
 
+ + +  (36) 
 NEFH 22q12.1-q13.1 Neurofilament, heavy 
polypeptide; 
cytoskeleton 
sporadic n/a + n/a  (37) 
 CHCHD10 22q11.23 Coiled-coil-helix-
coiled-coil-helix 
domain-containing 
protein 10; 
mitochondrial protein 
of the intermembrane 
space 
AD + + (11)   (38-42) 
 
AD, autosomal dominant; ALS, amyotrophic lateral sclerosis; AR, autosomal recessive; CMT, Charcot-Marie-Tooth; FTD, 
frontotemporal dementia; NEK1, NIMA (never in mitosis gene) kinase 1; PD, Parkinson’s disease; PMA, progressive muscular 
atrophy; SCA2, spinocerebellar atrophy 2 
n/a – no literature reports of either the association or lack of association of specific gene mutations with either FTD or ALS-FTD 
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1. Note failure to replicate the association with ALS in a second study (43;44).  This may imply a lack of association or a 
population-specific association. 
2. Single case reports of ALS-FTD and limb onset ALS with PGRN missense mutation variants of uncertain biological 
significance 
3. Initial report as a modifier of survival in ALS (2) have not been replicated (45;46) 
4. Initial reports as being associated with ALS (18;19) have not been replicated (47;48) 
5. Single variant identified in a mutational analysis (34); the bulk of the data relates specifically to neuropathological studies of 
the FET proteins in ALS.   
6. Single mutation (27) or sequence variants in both fALS and sALS (26). 
7. A single case report of ALS-FTD with a K171 ANG mutation (32). 
8. Initial report as a susceptibility gene for ALS have not been replicated (49) 
9. Single family in which ALS and FTD occur with a heterozygous R1101K mutation in the DCTN1 gene (50) 
10. A single family reported in which ALS and FTD occur; not replicated in French (51), Australian population studies (52) or 
Taiwanese (53) studies. 
11. Note several population studies in which no pathogenic mutations have been observed amongst specific geographic 
populations, suggesting a degree of regional specificity (54;55) 
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Supplemental Table 2.  Testing domains and testing paradigms recommended for the characterization of cognitive impairment in 
ALS. 
Executive Domain  Test Level 
I 
Level 
II 
Level 
III 
Executive function      
 Screening ALS-CBS (1) X X X 
 Screening & 
assessment 
ECAS (2) X 
 
X 
 
X 
 
 Fluency Verbal Fluency Index X X X 
 Concept formation Wisconsin Card Sorting Test (3)  X X 
  Card Sort from the Delis Kaplan 
Executive Function System (4) 
 X X 
 Divided Attention Trail Making Test (comparison 
between Trails B and A) (5) 
 X X 
 Attention-
inhibition 
Stroop Test (comparison 
between interference and control 
conditions) (6)  
 X X 
  Hayling Sentence Completion 
Test (7) 
 X X 
Social Cognition      
  Faux Pas  (8)  X X 
  Reading Mind in the Eyes  (9)  X X 
  Facial Emotional Expression 
(10)Test  
 X X 
  Judgement of Preference Test  
(11) 
  X 
Language 
 
     
  Assessment of Pragmatic 
Abilities and Cognitive 
Substrates (APACS) (12) 
  X 
  Picture description ([a] Picnic  X X 
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Scene Western Aphasia Battery; 
[b] 6-picture sequence (13) 
 Naming  
(pick one – select 
tests evaluate 
nouns + verbs) 
Boston Naming Test – Second 
edition 
*Full (14) or short-forms (15) 
X X X 
  An Object and Action Naming 
Battery (16) 
  X 
  Graded Naming Test (17)  X X 
  Expressive One-Word Picture 
Vocabulary Test – 4: Spanish-
Bilingual Edition (co-normed 
with Receptive One-Word 
Vocabulary Test – 4/English and 
Spanish) (18) 
 X X 
  Expressive Vocabulary Test -2 
(can be compared with PPVT IV 
scores) (19) 
 X X 
  Northwestern Naming Battery 
(nouns and verbs) (20) 
  X 
  Test of Adolescent/Adult Word 
Finding (TAWF-2; nouns and 
verbs) (21) 
 X X 
 Naming - Verbs 
only 
Action Naming Test 
http://www.bu.edu/lab/action-
naming-test/ 
  X 
 Semantic/Concepts Pyramids and Palm Trees 
(association task - objects) (22) 
 X X 
  Kissing and Dancing Test 
(association task – actions) (23) 
 X X 
 Single word 
comprehension 
Peabody Picture Vocabulary 
Test IV 
(24) 
X X X 
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  Receptive One-Word Picture 
Vocabulary Test – 4 (co-normed 
with Expressive One Word 
Vocabulary Test/English and 
Spanish) (18) 
 X X 
  Northwestern Naming Battery 
(25) 
  X 
 Receptive 
Grammar 
Test for Reception of Grammar 
– 2 (26) 
X X X 
  Northwestern Assessment of 
Verbs and Sentences (25)  
 X X 
 Syntax production Northwestern Assessment of 
Verbs and Sentences* (English; 
Spanish and Chinese versions in 
progress) (25) 
 X X 
  Northwestern Anagram Test 
Non-verbal measure of syntax 
production (27) 
 X X 
 Pragmatic/Social 
Language 
Pragmatic Protocol* (English)  
(28) 
  X 
  Lille Communication Test 
(French) (29) 
   
  Assessment of Pragmatic 
Abilities and Cognitive 
Substrates (APACS) (12) 
  X 
  Picture description ([a] Picnic 
Scene Western Aphasia Battery; 
[b] 6-picture sequences  (13;30) 
 X X 
 Spoken Language Topic Directed Interview (31)   X 
  Assessment of Pragmatic 
Abilities and Cognitive 
Substrates (APACS) (12) 
  X 
Memory      
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 Comprehensive 
testing 
Pick one of: 
 Repeatable Battery for the 
Assessment of 
Neuropsychological Status 
(RBANS) (32),  
 Rey Auditory Verbal 
Learning test (33) 
 California Verbal Learning 
test-II,(34) 
 Wechsler Memory Scale-IV, 
(35)  
 Rivermead Behavioural 
Memory test (36) 
 X X 
Behaviour      
 Screening Edinburgh Cognitive and 
Behavioural ALS Screen 
(Behavioural Screen) 
X X  
  ALS-CBS (Behavioural Screen) X X  
  MiND-B  X X 
  ALSFTD-Q  X X 
  FBI-ALS (37;38)  X X 
 
Note that while this listing contains a selection of tests which have been previously shown to be sensitive to ALS, the list is far from 
exhaustive.  As greater validation and experience in the use of domain-specific tests for the evaluation of FTSD occurs, it is 
expected that the testing paradigms recommended within each domain will be updated.  
  
Strong et al    
Frontotemporal syndromes of ALS  40 
Supplemental Table 3.  Characterization of ALSbi.  Behaviour and neuropsychiatric domains (adapted from Rascovksy et al 2011 
with the addition of psychosis and loss of insight) (1) 
Domain Symptom 
  
Behavioural disinhibition Socially inappropriate behaviour 
 Loss of manners or decorum 
 Impulsive, rash or careless actions 
Apathy or inertia (which must be 
differentiated from depression) 
Apathy 
 Inertia  
Loss of sympathy or empathy Diminished responsiveness to others people’s 
needs and feelings 
 Diminished social interest, interrelatedness or 
personal warmth 
Perseverative, stereotyped or 
compulsive/ritualistic behaviour 
Simple repetitive movements 
 Complex, compulsive or ritualistic behaviours 
 Stereotypy of speech 
Hyperorality and dietary changes Altered food preferences 
 Binge eating, increased consumption of 
alcohol or cigarettes 
Psychosis Delusions 
 Hallucinations 
Loss of insight Denial of, or lack of awareness regarding 
deficits 
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Table 1: ALS- causative genes and their association with ALS, FTD or ALS-FTSD (adapted from (142;143)) 
Locus Gene ID Chromosome Protein; functional 
changes 
Inheritance Clinical Phenotype Reference 
     FTD ALS ALS-
FTSD 
other  
ALS1 SOD1 21q22.11 Superoxide dismutase 1; 
Oxidative stress 
AD, AR  +  PLS, 
PMA 
(144) 
ALS2 ALS2 2q33.2 ALSin/Rho guanine 
nucleotide exchange 
factors 
AR  +  PLS, HSP (145;146) 
ALS4 SETX 9q34.13 Senataxin; DNA/RNA 
processing 
AD  +  AOA2 (147) 
ALS5 SPG11 15q21.1 Spatacsin; 
transmembrane protein 
AR  +  HSP (148;149) 
ALS6 FUS 16p11.2 Fused in Sarcoma; RNA 
binding protein, DNA 
repair, exon splicing 
AD + (#) + +  (150-152) 
ALS7 Unknown 20p13 Unknown AD  +   (153) 
ALS8 VAPB 20q13.33 Vesicle-associated 
membrane protein-
associated protein B and 
C; Altered axonal 
transport 
AD  +  SMA (154) 
ALS10 TARDBP 1p36.22 TAR DNA binding 
protein (TDP-43); 
DNA/RNA processing 
AD + + +  (155-157) 
ALS12 OPTN 10p13 Optineurin; membrane 
and vesicle trafficking, 
Protein degradation 
AD, AR  +  + (PDB) (158) 
ALS14 VCP 9q13.3 Valosin-containing 
protein; ATP-binding 
AD + + + MSP (159-161) 
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protein, vesicle transport 
and fusion 
ALS15 UBQLN2 X11p.21 Ubiquilin 2; 
ubiquitination, protein 
degradation 
X-linked + + +  (162-164) 
 PFN1 17p13.2 Profilin 1; actin binding 
protein, actin 
polymerization 
AD + +   (165-167) 
 HnRNPA2
B1/A1 
7p15.2/12q13.
3 
Heterogeneous nuclear 
ribonucleoprotein; 
mRNA processing 
AD  +  MSP (168;169) 
ALS-
FTD1 
Unknown 9q21-q22 Unknown AD + + +  (170) 
ALS-
FTD2 
C9orf72 9p21.2 *Chromosome 9 open 
reading frame 72; 
unknown 
AD + + +  (171-178) 
 TBK1 12q154.2 TANK-binding kinase 1; 
multifunctional kinase 
active in autophagosome-
mediated degradation of 
ubiquitinated proteins; 
also role in inflammatory 
signaling 
AD, sporadic + +   (179-184) 
 
AD, autosomal dominant; ALS, amyotrophic lateral sclerosis; AOA2, ataxia-ocular apraxia 2;AR, autosomal recessive; FTD, 
frontotemporal dementia; HSP, hereditary spastic paraplegia; MSP, multisystem proteinopathy (previously referred to as IBMFTD 
or inclusion body myopathy with Paget’s disease and frontotemporal dementia); PMA, progressive muscular atrophy; SMA, spinal 
muscular atrophy; TANK, TRAF family member-associated NF-kappa-B activator; TBK1, TANK-binding kinase 1 
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